FY2026 Earnings Forecast for Alumis Issued By HC Wainwright

Alumis Inc. (NASDAQ:ALMS) – Equities researchers at HC Wainwright issued their FY2026 EPS estimates for shares of Alumis in a research note issued to investors on Friday, May 23rd. HC Wainwright analyst M. Kapoor forecasts that the company will earn ($3.25) per share for the year. HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share.

Alumis (NASDAQ:ALMS) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of ($1.47) by ($0.35).

Several other equities analysts have also recently weighed in on ALMS. Oppenheimer lowered their price objective on shares of Alumis from $26.00 to $25.00 and set an “outperform” rating on the stock in a research note on Thursday, May 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research note on Thursday, March 20th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $24.86.

Alumis Trading Up 0.8%

Shares of NASDAQ:ALMS opened at $4.88 on Monday. The firm’s 50 day moving average price is $5.50 and its 200-day moving average price is $6.68. Alumis has a twelve month low of $3.18 and a twelve month high of $13.53.

Institutional Investors Weigh In On Alumis

A number of institutional investors have recently added to or reduced their stakes in ALMS. Foresite Capital Management VI LLC purchased a new stake in Alumis during the 4th quarter valued at approximately $33,033,000. Norges Bank purchased a new stake in Alumis during the 4th quarter valued at approximately $1,606,000. Foresite Capital Management V LLC grew its holdings in Alumis by 3.5% during the 4th quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock valued at $45,426,000 after buying an additional 194,459 shares in the last quarter. Tang Capital Management LLC grew its holdings in Alumis by 40.6% during the 4th quarter. Tang Capital Management LLC now owns 600,000 shares of the company’s stock valued at $4,716,000 after buying an additional 173,406 shares in the last quarter. Finally, BML Capital Management LLC purchased a new stake in Alumis during the 1st quarter valued at approximately $305,000.

Insiders Place Their Bets

In other news, major shareholder Foresite Labs, Llc bought 20,000 shares of the firm’s stock in a transaction on Tuesday, May 6th. The shares were bought at an average price of $4.34 per share, for a total transaction of $86,800.00. Following the purchase, the insider now owns 4,247,670 shares in the company, valued at approximately $18,434,887.80. The trade was a 0.47% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Alan Colowick bought 16,104 shares of the firm’s stock in a transaction on Tuesday, April 1st. The shares were purchased at an average price of $6.97 per share, for a total transaction of $112,244.88. Following the purchase, the director now owns 16,104 shares in the company, valued at $112,244.88. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 397,044 shares of company stock worth $1,891,895.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.